Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014456 | 0.92 | BCL2L1 (0.36) | BCL2L1BAD | |
| SCHEMBL17014324 | 0.88 | BCL2L1 (0.36) | BCL2L1BADESR1ESR2 | |
| SCHEMBL18199056 | 0.82 | ESR1 (0.37) | BCL2L1BADESR1ESR2POLB | |
| SCHEMBL17014494 | 0.81 | BCL2L1 (0.36) | BCL2L1BADESR1ESR2 | |
| SCHEMBL17014349 | 0.73 | — | — | |
| SCHEMBL17014371 | 0.73 | BCL2L1 (0.32) | BCL2L1BAD | |
| SCHEMBL17014328 | 0.69 | ALDH1A1 (0.41) | — | |
| SCHEMBL10802712 | 0.69 | BCL2L1 (0.50) | BCL2L1BADESR1ESR2 | |
| SCHEMBL3283307 | 0.69 | BCL2L1 (0.56) | BCL2L1BADESR1ESR2 | |
| SCHEMBL5644581 | 0.67 | BCL2L1 (0.46) | BCL2L1BADPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | BCL2L1 2670/4885BAD 1906/4885ESR1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.